Business UpdateJul 23, 2026, 08:07 AM
Bone Biologics Secures $3M Financing, Extends Runway to Q2 2027
AI Summary
Bone Biologics Corp issued a mid-year shareholder update highlighting progress across its 2026 priorities. The company completed a private placement, raising approximately $3.0 million in gross proceeds, which is expected to extend its operating runway through Q2 2027. This capital will support the advancement of its NB1 clinical program, manufacturing readiness, and intellectual property initiatives. The company also announced the extension of its rhNELL-1 protein's validated shelf life to 29 months and expects to complete patient enrollment in its first-in-human NB1 clinical study by year-end.
Key Highlights
- Completed a private placement generating approximately $3.0 million in gross proceeds.
- Financing included Series F and G warrants, potentially providing up to $6.0 million more if fully exercised.
- Net proceeds will fund clinical trials, patent portfolio, working capital, and general corporate purposes.
- Financing extends the company's operating runway through Q2 2027.
- Patient enrollment in the NB1 clinical study is expected to complete by year-end 2026.
- Validated shelf life of rhNELL-1 protein extended to 29 months.
Price Impact
More from BBLG